These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

100 related items for PubMed ID: 2643392

  • 21. [Evaluation of chemotherapy of hematological malignancies].
    Masaoka T.
    Gan To Kagaku Ryoho; 1989 Mar; 16(3 Pt 1):316-22. PubMed ID: 2649005
    [Abstract] [Full Text] [Related]

  • 22. Decitabine improves overall survival in myelodysplastic syndromes-RAEB patients aged ≥60 years and has lower toxicities: Comparison with low-dose chemotherapy.
    Ye L, Ren Y, Zhou X, Mei C, Xu W, Ma L, Luo Y, Hu C, Ye X, Wei J, Lou Y, Jin J, Tong H.
    Blood Cells Mol Dis; 2019 Jul; 77():88-94. PubMed ID: 31005752
    [Abstract] [Full Text] [Related]

  • 23. Treatment of myelodysplastic syndromes with orally administered N-(2S, 3R)-3-amino-2-hydroxy-4-phenylbutyryl-L-leucine (ubenimex).
    Fukutani H, Naoe T, Saito H, Ohshima T, Omine M, Miura Y, Mizoguchi H, Kimura I, Tomonaga M, Ohno R.
    Jpn J Clin Oncol; 1991 Aug; 21(4):287-92. PubMed ID: 1942558
    [Abstract] [Full Text] [Related]

  • 24. [Successful treatment of a 74-year-old man with refractory anemia with excess of blasts in transformation (RAEB in T) by low-dose Ara-C injection].
    Wataya S, Sudou H, Sakamaki I, Wano Y, Ueda T, Nakamura T.
    Nihon Ronen Igakkai Zasshi; 1995 Jun; 32(6):438-41. PubMed ID: 7563939
    [Abstract] [Full Text] [Related]

  • 25. Hematologic improvement and response in elderly AML/RAEB patients treated with valproic acid and low-dose Ara-C.
    Corsetti MT, Salvi F, Perticone S, Baraldi A, De Paoli L, Gatto S, Pietrasanta D, Pini M, Primon V, Zallio F, Tonso A, Alvaro MG, Ciravegna G, Levis A.
    Leuk Res; 2011 Aug; 35(8):991-7. PubMed ID: 21474179
    [Abstract] [Full Text] [Related]

  • 26. [Low dose all-trans retinoic acid and androgen therapy for patients with myelodysplastic syndrome].
    Guan M, Chen SC, Li RS, Ge CW, Zhu HL.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2004 Dec; 12(6):774-8. PubMed ID: 15631659
    [Abstract] [Full Text] [Related]

  • 27. Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes, acute myeloid leukaemia, or chronic myelomonocytic leukaemia: results of a real-life, non-interventional post-marketing survey.
    Beguin Y, Selleslag D, Meers S, Graux C, Bries G, Deeren D, Vrelust I, Ravoet C, Theunissen K, Voelter V, Potier H, Trullemans F, Noens L, Mineur P.
    Acta Clin Belg; 2015 Feb; 70(1):34-43. PubMed ID: 25444072
    [Abstract] [Full Text] [Related]

  • 28. Primary myelodysplastic syndrome: an analysis of 56 patients.
    Chen PH, Kuo CY, Huang CH, Shih LY.
    Changgeng Yi Xue Za Zhi; 1992 Sep; 15(3):121-7. PubMed ID: 1468034
    [Abstract] [Full Text] [Related]

  • 29. [Cyclosporine A based therapy for myelodysplastic syndrome].
    Li ZL, Gong M, Xu SH, Huang FZ, Chen YR, Ma YG.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Oct; 13(5):867-70. PubMed ID: 16277860
    [Abstract] [Full Text] [Related]

  • 30. Oral idarubicin as treatment for advanced myelodysplastic syndrome.
    Lowenthal RM, Lambertenghi-Deliliers G.
    Haematologica; 1991 Oct; 76(5):398-401. PubMed ID: 1806444
    [Abstract] [Full Text] [Related]

  • 31. Treatment of myelodysplastic syndromes with orally administered 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate.
    Ohno R, Tatsumi N, Hirano M, Imai K, Mizoguchi H, Nakamura T, Kosaka M, Takatsuki K, Yamaya T, Toyama K.
    Oncology; 1991 Oct; 48(6):451-5. PubMed ID: 1749580
    [Abstract] [Full Text] [Related]

  • 32. Evaluation of CI-973, a platinum analogue, in refractory or relapsed acute leukemia.
    Kantarjian HM, Beran M, O'Brien S, Robertson L, Siddik Z, Yoshida M, Yang LY, Rios MB, Keating MJ, Meyer M.
    Leukemia; 1996 Mar; 10(3):396-401. PubMed ID: 8642853
    [Abstract] [Full Text] [Related]

  • 33. Topotecan-based combination chemotherapy in patients with transformed chronic myelogenous leukemia and advanced myelodysplastic syndrome.
    Park SJ, Kim DW, Kim HJ, Eom HS, Min CK, Lee JW, Min WS, Kim CC.
    Korean J Intern Med; 2000 Jul; 15(2):122-6. PubMed ID: 10992724
    [Abstract] [Full Text] [Related]

  • 34. [Therapeutic effect of ranimustine(MCNU) on myeloproliferative disorder and chronic myelomonocytic leukemia].
    Maeda S, Okabe M, Kurosawa M, Kunieda Y, Imamura M, Morioka M, Sakurada K, Miyazaki T, Sukegawa M.
    Gan To Kagaku Ryoho; 1991 Feb; 18(2):251-8. PubMed ID: 1992919
    [Abstract] [Full Text] [Related]

  • 35. [Long-term effects of androgen combined with low dose all-trans-retinoic acid on myelodysplastic syndrome: follow-up of 60 cases].
    Guan M, Chen SC, Ge CW.
    Zhonghua Yi Xue Za Zhi; 2009 Apr 07; 89(13):919-22. PubMed ID: 19671296
    [Abstract] [Full Text] [Related]

  • 36. A randomized phase II study of low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in myelodysplastic syndromes (MDS) with a high risk of developing leukemia. EORTC Leukemia Cooperative Group.
    Gerhartz HH, Marcus R, Delmer A, Zwierzina H, Suciu S, Dardenne M, Solbu G, de Witte T, Jacobs A, Visani G.
    Leukemia; 1994 Jan 07; 8(1):16-23. PubMed ID: 8289481
    [Abstract] [Full Text] [Related]

  • 37. Anti-Leukemia Chemotherapy of High-Risk Myelodysplastic Syndromes.
    Tohyama K, Tsutani H, Wano Y, Iwasaki H, Fukushima T, Urasaki Y, Kawai Y, Nakamura T, Yoshida Y, Ueda T.
    Oncologist; 1997 Jan 07; 2(3):160-163. PubMed ID: 10388046
    [Abstract] [Full Text] [Related]

  • 38. Prospective comparison of 5- and 7-day administration of azacitidine for myelodysplastic syndromes: a JALSG MDS212 trial.
    Miyazaki Y, Kiguchi T, Sato S, Usuki K, Ishiyama K, Ito Y, Suzuki T, Taguchi J, Chiba S, Dobashi N, Tomita A, Harada H, Handa H, Horiike S, Maeda T, Matsuda M, Ichikawa M, Hata T, Honda S, Iyama S, Suzushima H, Moriuchi Y, Kurokawa T, Yokota K, Ohtake S, Yamauchi T, Matsumura I, Kiyoi H, Naoe T, Japan Adult Leukemia Study Group.
    Int J Hematol; 2022 Aug 07; 116(2):228-238. PubMed ID: 35508695
    [Abstract] [Full Text] [Related]

  • 39. Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.
    Giles FJ, Faderl S, Thomas DA, Cortes JE, Garcia-Manero G, Douer D, Levine AM, Koller CA, Jeha SS, O'Brien SM, Estey EH, Kantarjian HM.
    J Clin Oncol; 2003 Mar 15; 21(6):1050-6. PubMed ID: 12637470
    [Abstract] [Full Text] [Related]

  • 40. Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia.
    Giles FJ, Garcia-Manero G, Cortes JE, Baker SD, Miller CB, O'Brien SM, Thomas DA, Andreeff M, Bivins C, Jolivet J, Kantarjian HM.
    J Clin Oncol; 2002 Feb 01; 20(3):656-64. PubMed ID: 11821445
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.